Zoetis Inc. revenue by segment ZTS

Annual Quarterly

Zoetis Inc. splits its revenue into 14 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Total Productsand Services at $2.4 billion, 99% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	9,494	2,391	2,468	2,262	2,373	2,422	2,474	2,198	2,317
Total Productsand Services	—	2,362 -1.4% share 98.8%	2,439 -0.1% share 98.8%	2,239 +3.3% share 99.0%	2,357 +2.7% share 99.3%	2,396 share 98.9%	2,441 share 98.7%	2,168 share 98.6%	2,296 share 99.1%
Parasiticides	—	—	—	—	—	—	—	—	519 share 22.4%
Dermatology	—	—	—	—	429 +1.9% share 18.1%	—	—	—	421 share 18.2%
Anti Infective Products	—	—	—	—	284 share 12.0%	—	—	—	—
Pain Sedation	—	—	—	—	209 share 8.8%	200 share 8.3%	—	—	—
Other Pharmaceuticals	—	—	168 share 6.8%	158 share 7.0%	188 +4.4% share 7.9%	—	—	—	180 share 7.8%
Animal Health Diagnostics	—	—	123 +11.8% share 5.0%	117 share 5.2%	111 +11.0% share 4.7%	112 share 4.6%	110 share 4.4%	—	100 share 4.3%
Fish	—	—	83 +2.5% share 3.4%	66 +20.0% share 2.9%	—	—	81 share 3.3%	55 share 2.5%	—
Horses	—	73 +5.8% share 3.1%	74 +4.2% share 3.0%	76 +18.8% share 3.4%	6,080 +4.8% share 256.2%	69 share 2.8%	71 share 2.9%	64 share 2.9%	5,801 share 250.4%
Other Non Pharmaceuticals	—	68 share 2.8%	70 +2.9% share 2.8%	66 -7.0% share 2.9%	70 +7.7% share 2.9%	—	68 share 2.7%	71 share 3.2%	65 share 2.8%
Manufactured Product Other	—	32 +10.3% share 1.3%	26 +4.0% share 1.1%	21 +5.0% share 0.9%	18 share 0.8%	29 share 1.2%	25 share 1.0%	20 share 0.9%	—
Contract Manufacturingand Human Health Diagnostics	—	29 +11.5% share 1.2%	29 -12.1% share 1.2%	23 -23.3% share 1.0%	—	26 share 1.1%	33 share 1.3%	30 share 1.4%	—
Medicated Feed Additives	—	—	—	—	12 -76.5% share 0.5%	5 share 0.2%	—	—	51 share 2.2%
Dogs And Cats	—	—	—	—	-4,479 -5.9% share -188.7%	—	—	—	-4,231 share -182.6%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ZTS (NYSE)
Fiscal year ends: December 31
Headquarters: Parsippany, NJ
SEC filer status: Large accelerated filer
SEC CIK: 1555280

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.